Pharmadelic Labs

Research

Pharmadelic Labs aims to develop a portfolio of intellectual property around biosynthesis pathways for creating compounds. This has great potential for application in the pharmaceuticals industry.

The company's patent portfolio will develop as follows:

File for provisional patent applications
Continue to update patents as technology develops
Strengthen existing patents with further applications around biosynthesis pathways as results are known

Here’s how the biosynthesis of psilocybin works:

Step 1

Order synthetic DNA from hallucinogenic mushrooms

Step 2

Install DNA into genome of industrial brewing yeast

Step 3

Cultivate yeast on a large scale

Step 4

Extract psilocybin

Step 5

Create pharmaceutical products

THE OPTIMAL PROCESS

Pharmadelic Labs’ biosynthesis process is clean and economical, and much quicker than cultivating mushrooms by themselves – 3 days rather than 10 weeks. It also ensures consistent levels of psilocybin and is safe due to yeast’s status as Generally Recognized As Safe (GRAS).

Pharmadelic Labs will also be providing an effective alternative to chemical synthesis. Chemical synthesis of psilocybin costs upwards of $7,000 per gram, which is far more expensive than our methods

RESEARCH

Peer-reviewed studies have already been published about the potential benefits of psychoactive substances (including psilocybin) for mental health. Examples of research can be found here.

Ross, Stephen, et al. “Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.” Journal of psychopharmacology 30.12 (2016): 1165-1180

Griffiths, Roland R., et al. “Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.” Journal of psychopharmacology 30.12 (2016): 1181-1197

Carhart-Harris, Robin L., et al. “Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.” The Lancet Psychiatry 3.7 (2016): 619-627

Belouin, Sean J., and Jack E. Henningfield. “Psychedelics: Where we are now, why we got here, what we must do.” Neuropharmacology 142 (2018): 7-19

Johnson, Matthew W., et al. “The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act.” Neuropharmacology 142 (2018): 143-166